Patients with CP‐CML whose disease becomes resistant to a 2G BCR::ABL1 TKI, either with or without a BCR::ABL1 kinase domain mutation, experience low response rates, and poor long‐term outcomes if treated with another 2G BCR::ABL1 TKI.5, 6. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.